Skip to main content
TipRanks
Go Ultimate75% OFF

Sectra AB Class B (SECT.B) AI Stock Analysis

4 Followers
SE:SECT.B

Sectra AB Class B

(Nasdaq OMX AB:SECT.B)

Select Model
Rating:74Outperform
Price Target:SEK 360.00â–²(9.96% Upside)
Action:reiterated
Date:09/07/26

The score is driven primarily by strong financial quality (profitability and a very low-leverage balance sheet) and supportive uptrend/momentum signals. The main constraint is valuation: a very high P/E and low dividend yield reduce the risk-adjusted attractiveness despite solid fundamentals.

Positive Factors
Strong profitabilityHigh net and operating margins indicate that Sectra converts revenue into substantial earnings while maintaining effective cost control. This profitability provides internal funding for product development, customer support, and international expansion, supporting durable earnings quality over the next several quarters.
Negative Factors
Slowing revenue growthThe moderation in top-line growth suggests Sectra is entering a more mature phase, which may make it harder to sustain rapid earnings expansion. Slower revenue growth can also reduce operating leverage and limit the pace at which the company broadens its installed customer base.

Sectra AB Class B (SECT.B) vs. iShares MSCI Sweden ETF (EWD)

-40%-30%-20%-10%0%10%20%30%SE:SECT.B+18.11%EWD+15.85%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 62.79B
Dividend Yield
0.71%
Average Volume (3M)
185.16K
Price to Earnings (P/E)
98.4
Beta (1Y)
0.46
Revenue Growth
13.94%
EPS Growth
5.70%
Country
Sweden
Employees
1,403
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Sectra AB Class B Business Overview & Revenue Model

Company Description

Sectra AB (publ), a Swedish company established in Linköping in 1957, specializes in providing advanced information technology solutions for both the medical and cybersecurity fields. Its services are predominantly offered across Europe, including ke...

How the Company Makes Money

Sectra makes money primarily by selling and supporting software and systems in two main areas: (1) Medical imaging IT and (2) secure communications. In its medical imaging business, Sectra generates revenue from supplying imaging and workflow softwar...

Sectra AB Class B Financial Statement Overview

Summary

Strong overall fundamentals supported by high profitability (net margin ~16.6%, operating profitability >~20%) and a very conservative balance sheet (low debt/equity ~0.055, strong return on shareholder capital ~30%). Offsets are moderating revenue growth (~5.6% TTM) and a year-over-year decline in free cash flow (~-14% TTM), which slightly reduces confidence in consistency.

Income Statement

82Very Positive

Balance Sheet

90Very Positive

Cash Flow

74Positive
Financial statement breakdown
BreakdownTTMApr 2025Apr 2024Apr 2023Apr 2022Apr 2021
Income Statement
Total Revenue3.74B3.54B3.24B2.96B2.35B1.95B
Gross Profit924.81M714.42M543.41M557.55M488.91M1.71B
EBITDA843.14M778.66M842.12M654.12M573.39M477.28M
Net Income618.99M563.78M563.37M428.39M374.96M314.79M
Balance Sheet
Total Assets4.49B4.47B3.76B3.21B2.74B2.19B
Cash, Cash Equivalents and Short-Term Investments1.75B1.81B1.34B804.64M945.24M808.77M
Total Debt127.64M76.48M87.46M31.79M82.26M62.62M
Total Liabilities2.17B2.34B1.84B1.64B1.44B1.11B
Stockholders Equity2.32B2.14B1.92B1.57B1.30B1.08B
Cash Flow
Free Cash Flow848.87M1.01B812.37M75.58M347.70M542.55M
Operating Cash Flow981.92M1.10B922.36M326.33M440.49M616.92M
Investing Cash Flow-230.54M-207.46M-113.86M-130.74M-212.79M-68.35M
Financing Cash Flow-430.11M-428.43M-251.88M-222.20M-219.29M-198.75M

Sectra AB Class B Technical Analysis

Technical Analysis SentimentPositive
Last Price327.40

Price Trends

50DMA307.82Positive
100DMA292.49Positive
200DMA266.57Positive

Market Momentum

MACD3.24Positive
RSI51.30Neutral
STOCH20.73Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SECT.B, the sentiment is Positive. The current price of 327.40 is below the 20-day moving average (MA) of 329.04, above the 50-day MA of 307.82, and above the 200-day MA of 266.57, indicating a neutral trend. The MACD of 3.24 indicates Positive momentum. The RSI at 51.30 is Neutral, neither overbought nor oversold. The STOCH value of 20.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SECT.B.

Sectra AB Class B Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:SECT.B against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CEVISE:CEVI83OutperformSEK 4.85B35.2115.23%1.35%1.95%-8.91%
SE:SECT.BSE:SECT.B74OutperformSEK 62.79B98.4130.26%0.71%13.94%5.70%
SE:GETI.BSE:GETI.B67NeutralSEK 76.70B27.109.13%1.69%-3.90%37.73%
SE:XVIVOSE:XVIVO64NeutralSEK 6.49B50.375.89%―17.83%330.94%
SE:VITRSE:VITR63NeutralSEK 16.15B-3.26-61.57%0.92%-1.94%-1223.74%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:MNTCSE:MNTC51NeutralSEK 455.64M-24.13-15.00%―11.18%60.51%

* Healthcare Sector Average

Performance Comparison

0%50%SE:SECT.BSE:GETI.BSE:VITRSE:CEVISE:XVIVOSE:MNTCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:SECT.B and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:SECT.BSectra AB Class B327.4046.6416.61%
SE:GETI.BGetinge AB (UK)282.3080.1639.66%
SE:VITRVitrolife AB119.10-18.98-13.75%
SE:CEVICellaVision AB203.5053.2435.43%
SE:XVIVOXvivo Perfusion AB198.4036.0022.17%
SE:MNTCMentice AB16.903.6027.07%

Sectra AB Class B Corporate Events

Sectra Breaks SEK 1 Billion Mark in Cloud Recurring Revenue

Sep 4, 2026

Sectra reported that its rolling 12-month cloud recurring revenue passed SEK 1 billion for the first time, driven by strong historical order bookings and long-term investments in scalable cloud services. The company’s recurring revenue now makes up a...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 07, 2026